Onkologie. 2022:16(3):155-158 | DOI: 10.36290/xon.2022.030

Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax

Miloslava Hisemová, Václav Ptáčník
Ústav hematologie a krevní transfuze, Klinický úsek, Praha
Ústav nukleární medicíny, VFN a 1. LF UK, Praha

The case report presents a female patient with multifocal myeloid sarcoma in the soft tissues, skin, and lymph nodes in the presence of concomitant myelodysplastic syndrome in whom two series of inpatient induction chemotherapy (high-dose cyta­rabine and mitoxantrone, i.e. the HAM protocol) failed to induce complete remission and resolution of extramedullary lesions. Combined outpatient treatment with azacitidine (a hypomethylating agent) and venetoclax (a Bcl-2 inhibitor) has been shown to have a potential to overcome tumour chemoresistance.

Keywords: myeloid sarcoma, leukaemia cutis, chemotherapy, venetoclax, azacitidine.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hisemová M, Ptáčník V. Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax. Onkologie. 2022;16(3):155-158. doi: 10.36290/xon.2022.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shallis RM, Gale RP, Lazarus HM, et al. Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Rev. 2021;47:100773. Go to original source... Go to PubMed...
    2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Go to original source... Go to PubMed...
    3. Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785-3793. Go to original source... Go to PubMed...
    4. Faaij CM, Willemze AJ, Révész T, et al. Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: differential roles for CCR2, CCR5, CXCR4 and CXCR7. Pediatr Blood Cancer. 2010;55(2):344-348. Go to original source... Go to PubMed...
    5. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007;137(4):288-296. Go to original source... Go to PubMed...
    6. Ganzel C, Manola J, Douer D, et al. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol. 2016;34(29):3544-3553. Go to original source... Go to PubMed...
    7. Almond LM, Charalampakis M, Ford SJ, et al. Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263-267. Go to original source... Go to PubMed...
    8. Gornicec M, Wölfler A, Stanzel S, et al. Evidence for a role of decitabine in the treatment of myeloid sarcoma. Ann Hematol. 2017;96(3):505-506. Go to original source... Go to PubMed...
    9. Kanate AS, Vos J, Chargualaf MJ. Venetoclax for Refractory Myeloid Sarcoma. J Oncol Pract. 2019;15(7):413-415. Go to original source... Go to PubMed...
    10. Wang HQ, Li J. Clinicopathological features of myeloid sarcoma: Report of 39 cases and literature review. Pathol Res Pract. 2016;212(9):817-824. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.